Amylyx Pharmaceuticals, Inc. AMLX R2KR3KPHARMA
Company Overview
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +227.71% |
| 6 Months: | +59.62% |
| 3 Months: | +39.56% |
| 1 Month: | -9.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 31.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMLX Amylyx Pharmaceuticals, Inc. R2KR3KPHARMA | 27.20 | -19.29 | $3.41B | 0.00% | -49.46% | -74.73% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 345.00K | 71.43M | 98.22M | 102.69M | 88.64M | -1.02M | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.80M | 42.86M | 36.03M | 36.60M | 43.78M | - |
| Operating Income | -12.87M | -18.59M | -22.92M | -47.81M | -54.25M | -54.68M | -2.05M | 20.20M | 18.72M | -122.13M | -76.29M | - | - | -37.80M | -42.86M | -36.03M | -36.60M | -43.78M | -45.69M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.65M | -42.72M | -35.91M | -36.50M | -43.68M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -35.91M | -41.44M | -34.39M | -32.95M | -41.28M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -635.00K | 0 | 0 | 0 | 46.00K | - | - |
| Net Income | -14.52M | -21.92M | -23.14M | -47.85M | -54.07M | -53.76M | 1.57M | 22.07M | 20.89M | -118.79M | -72.70M | - | - | -35.91M | -41.44M | -34.39M | -33.00M | -41.28M | -43.42M |
| Diluted EPS | - | -3.41 | -3.42 | -0.93 | -0.93 | -0.92 | 0.02 | 0.31 | 0.30 | -1.75 | -1.07 | - | - | -0.42 | -0.46 | -0.37 | -0.30 | -0.37 | -0.39 |
| R&D Expense | 6.86M | 10.93M | 12.85M | 21.46M | 24.26M | 24.91M | 24.19M | 29.04M | 30.04M | 36.61M | 23.35M | 21.24M | - | 22.12M | 27.22M | 19.86M | - | 27.61M | 23.77M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 22.23M | 380.79M | 87.37M | 0 |
| Cost of Revenue | - | 2.99M | 25.44M | 124.63M | 0 |
| Gross Profit | - | 19.24M | 355.35M | -37.26M | 0 |
| Operating Expenses | - | 220.58M | 316.54M | 218.41M | 153.29M |
| Operating Income | - | -201.34M | 38.80M | -255.68M | -153.29M |
| EBITDA | - | -200.85M | 39.89M | -254.77M | -152.77M |
| Interest Expense | 0 | - | - | - | - |
| Pretax Income | - | -197.60M | 54.30M | -302.14M | -144.69M |
| Tax Provision | - | 774.00K | 5.03M | -393.00K | 46.00K |
| Net Income | - | -198.38M | 49.27M | -301.74M | -144.74M |
| Diluted EPS | - | -3.39 | 0.70 | -4.43 | -1.53 |
| R&D Expense | 44.04M | 93.45M | 128.19M | 104.08M | 90.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 391.45M | 517.45M | 193.63M | 332.64M |
| Current Assets | - | - | 382.13M | 464.67M | 189.43M | 323.67M |
| Cash & Equivalents | - | - | 62.53M | 170.20M | 77.39M | 226.65M |
| Inventory | - | 0 | 9.77M | 38.32M | 0 | - |
| Receivables | - | - | 15.31M | 40.05M | 447.00K | 88.00K |
| Total Liabilities | - | - | 50.85M | 84.02M | 28.87M | 27.39M |
| Current Liabilities | - | - | 46.61M | 82.04M | 28.41M | 22.69M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 6.28M | 4.24M | 1.98M | 5.96M |
| Total Equity | -66.72M | - | 340.61M | 433.43M | 164.76M | 305.26M |
| Shares Outstanding | - | - | 66.51M | 67.71M | 68.63M | 109.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -179.87M | 11.92M | -167.65M | -123.34M |
| Investing Cash Flow | - | -238.99M | 92.05M | 75.65M | 14.04M |
| Financing Cash Flow | - | 431.79M | 3.54M | 348.00K | 257.03M |
| Capital Expenditure | - | -2.53M | -1.24M | -157.00K | -138.00K |
| Free Cash Flow | - | -182.40M | 10.68M | -167.80M | -123.48M |
| Net Change in Cash | - | 12.93M | 107.52M | -91.64M | 147.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 86.5% | 93.3% | -42.6% | - |
| Operating Margin % | - | -905.7% | 10.2% | -292.6% | - |
| Net Margin % | - | -892.4% | 12.9% | -345.4% | - |
| ROE % | - | -58.2% | 11.4% | -183.1% | -47.4% |
| ROCE % | - | -58.4% | 8.9% | -154.7% | -49.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 15.01% | 16.73M | $470.72M |
| 2 | Blackrock Inc. | 7.92% | 8.83M | $248.39M |
| 3 | Perceptive Advisors Llc | 7.48% | 8.33M | $234.54M |
| 4 | TCG Crossover Management, LLC | 5.60% | 6.24M | $175.70M |
| 5 | Commodore Capital Lp | 5.07% | 5.65M | $158.99M |
| 6 | Jupiter Topco LLC | 4.70% | 5.24M | $147.34M |
| 7 | Saturn V Capital Management LP | 4.15% | 4.62M | $130.12M |
| 8 | Vanguard Capital Management LLC | 3.79% | 4.22M | $118.87M |
| 9 | Morgan Stanley | 2.81% | 3.13M | $88.10M |
| 10 | Driehaus Capital Management, LLC | 2.73% | 3.04M | $85.46M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMLX
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass., October 06, 2026--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting
Amylyx Pharmaceuticals And 2 More Quality Growth Stocks
The Federal Reserve just lifted interest rates again to tackle stubborn inflation, which puts real pressure on weaker balance sheets and slow growing businesses. In this environment, investors may focus on companies that analysts expect to …
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Fo…
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
FRAMINGHAM, Mass., September 09, 2026--Tortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both su…
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass., September 08, 2026--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
AMLX — Frequently Asked Questions
What is the current share price of Amylyx Pharmaceuticals, Inc. (AMLX)?
As of 2026-10-23 16:27 PDT, Amylyx Pharmaceuticals, Inc. (AMLX) trades at $27.20 on NasdaqGS. Its 52-week range is $7.82 to $39.66.
What is the market capitalisation of AMLX?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalisation of $3.41B on NasdaqGS.
What is the P/E ratio of AMLX?
AMLX trades at a trailing price-to-earnings (P/E) ratio of -19.29. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 13.10.
What is the return on equity (ROE) of AMLX?
AMLX has a return on equity (ROE) of -74.73%. Its return on capital employed (ROCE) is -49.46%.
Is AMLX a good stock to buy?
This page provides a data-driven analysis of Amylyx Pharmaceuticals, Inc. (AMLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.